Jong Soo Lee

Prof. Dr. Jong Soo Lee

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2017 in Trials
Verified
Journal Article
Open access
PDF file
HJHee-Yeon Jung
Hee-Yeon Jung
SSSook Jin Seong
Sook Jin Seong
JCJi-Young Choi
Ji-Young Choi
Jang-Hee ChoJang-Hee Cho
Jang-Hee Cho
SPSun-Hee Park
Sun-Hee Park
Yong-Lim KimYong-Lim Kim
Yong-Lim Kim
Immunosuppression non-adherence in kidney transplant recipients (KTRs) not only increases the risk of medical intervention due to acute rejection and graft loss but burdens the socioeconomic system in the form of increased healthcare costs. An aggressive preemptive effort by healthcare professionals, geared to ensure adherence to immunosuppressants in KTRs, is significant and imperative. This study was designed as a prospective, open-label, multicenter, randomized controlled study aimed at evaluating the efficacy and stability of an information and communication technology (ICT)-based centralized monitoring system in boosting medication adherence in KTRs. One hundred fourteen KTRs registered throughout the year 2017 to 2018 are randomized into either the ICT-based centralized home monitoring system or to ambulatory follow-up. The planned follow-up duration is 6 months. The ICT-based centralized home monitoring system described consists of a smart pill box equipped with personal identification system, a home monitoring system, an electronic Case Report Form (eCRF) system, and a comprehensive clinical trial management system (CTMS). It alerts both patients and medical staff with texts and pill box alarms if there is a dosage/dosing time error or a missed dose. Medication adherence and transplant outcomes for the follow-up period are compared between the two groups, while patient satisfaction as well as the stability and cost-effectiveness of the ICT-based monitoring system are to be evaluated. This on-going study is expected to determine if consistent use of the ICT-based centralized monitoring system described could maximize mediation adherence and subsequently enhance transplant outcomes in KTRs. Further, it would lay the foundation for successful implementation of this ICT-based monitoring system for effective management of medication adherence in KTRs. ClinicalTrials.gov, Identifier: NCT03136588 . Registered on 20 April 2017.

22 October 2014 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
CPChuiyoung Park
Chuiyoung Park
SCSeung Won Choi
Seung Won Choi
MKMisung Kim
Misung Kim
JPJongha Park
Jongha Park
JLJong Soo Lee
Jong Soo Lee
HCHyun Chul Chung
Hyun Chul Chung
Hypocomplementemic urticarial vasculitis syndrome is a rare disorder characterized by chronic urticarial vasculitis, arthralgia, arthritis, and hypocomplementemia. Previously, only six patients with concomitant hypocomplementemic urticarial vasculitis syndrome, Jaccoud’s arthropathy, and valvular heart disease have been reported.

1 January 2020 in Immune Network
Verified
Journal Article
Open access
NNNu Z. N. Nguyen
Nu Z. N. Nguyen
VTVuvi G. Tran
Vuvi G. Tran
SLSaerom Lee
Saerom Lee
MKMinji Kim
Minji Kim
SKSang W. Kang
Sang W. Kang
Byungsuk KwonByungsuk Kwon
Byungsuk Kwon
Nguyen NZ, et al. Immune Netw. 2020 Nov;20(6):e49. https://doi.org/10.4110/in.2020.20.e49

Verified
Journal Article
Open access
PDF file
JLJeong-Hoon Lim
Jeong-Hoon Lim
BCByung Ha Chung
Byung Ha Chung
SLSang Ho Lee
Sang Ho Lee
JLJong Soo Lee
Jong Soo Lee
YKYeong Hoon Kim
Yeong Hoon Kim
Chan-Duck KimChan-Duck Kim
Chan-Duck Kim
Acute rejection (AR) is critical for long-term graft survival in kidney transplant recipients (KTRs). This study aimed to evaluate the efficacy of the integrated risk score of omics-based biomarkers in predicting AR in KTRs. This prospective, randomized, controlled, multicenter, pilot study enrolled 40 patients who recently underwent high-immunologic-risk kidney transplantation (KT). Five omics biomarkers were measured, namely, blood mRNA (three-gene signature), urinary exosomal miRNA (three-gene signature), urinary mRNA (six-gene signature), and two urinary exosomal proteins (hemopexin and tetraspanin-1) at 2 weeks and every 4 weeks after KT for 1 year. An integrated risk score was generated by summing each biomarker up. The biomarker group was informed about the integrated risk scores and used to adjust immunosuppression, but not the control group. The outcomes were graft function and frequency of graft biopsy. Sixteen patients in the biomarker group and nineteen in the control group completed the study. The mean estimated glomerular filtration rate after KT did not differ between the groups. Graft biopsy was performed in two patients (12.5%) and nine (47.4%) in the biomarker and control groups, respectively, with the proportion being significantly lower in the biomarker group (p = 0.027). One patient (6.3%) in the biomarker group and two (10.5%) in the control group were diagnosed with AR, and the AR incidence did not differ between the groups. The tacrolimus trough level was significantly lower in the biomarker group than in the control group at 1 year after KT (p = 0.006). Integrated omics biomarker monitoring may help prevent unnecessary or high-complication-risk biopsy and enables tailored immunosuppression by predicting the risk of AR in KTRs.

1 June 2019 in Clinical Nephrology
Verified
Journal Article
Closed access
KPKyung Sun Park
Kyung Sun Park
SPSang Jun Park
Sang Jun Park
HPHojong Park
Hojong Park
MKMisung Kim
Misung Kim
JPJongha Park
Jongha Park
JLJong Soo Lee
Jong Soo Lee
Background: Donor organ quality is a key determinant of graft outcomes in deceased donor kidney transplantation (DDKT). The predictive values of baseline histopathology and several clinical scoring systems for long-term graft outcomes have been evaluated, but the results remain controversial. Materials and methods: We screened 167 patients who underwent DDKT at Ulsan University Hospital from April 2003 to June 2016. Among them, 66 patients who underwent baseline kidney biopsy and whose kidney donor risk index (KDRI) was available were included in this analysis. All baseline biopsies were rescored according to the updated Banff classification. Results: Median follow-up was 22 months. Mean age of recipients and donors was 51.4 and 44.7 years, respectively. Mean KDRI was 1.40 +/- 0.44. During follow-up, delayed graft function and biopsy-proven acute rejection (BPAR) developed in 7 and 11 patients, respectively. Graft failure occurred in 2 patients. In Cox regression analysis, interstitial fibrosis/tubular atrophy (IFTA) (hazard ratio (HR) = 3.59; p = 0.049) was a significant risk factor for BPAR. In multivariate linear regression, age (standardized beta (SB) = -0.282; p = 0.002), BPAR (SB = -0.406; p < 0.001), KDRI (SB = -0.277; p = 0.003), and IFTA (SB = -0.298; p = 0.001) were significant predictors of last-visit estimated glomerular filtration rate (eGFR). Conclusion: Several clinical and pathologic parameters, such as KDRI and IFTA, may be helpful for predicting long-term graft outcomes, including BPAR and last-visit eGFR, in DDKT.

9 September 2022 in Medicine
Verified
Journal Article
Open access
JSJe Hun Song
Je Hun Song
HHHyuk Huh
Hyuk Huh
EBEunjin Bae
Eunjin Bae
JLJeonghwan Lee
Jeonghwan Lee
JLJung Pyo Lee
Jung Pyo Lee
KYKyung Don Yoo
Kyung Don Yoo
Hyperhomocysteinemia (HHcy) is considered a risk factor for cardiovascular disease (CVD), including chronic kidney disease (CKD). In this study, we investigated the association between levels of serum homocysteine (Hcy) and mortality, inferred from the presence of CKD. Our study included data of 9895 participants from the 1999 to 2016 National Health and Nutrition Examination Surveys (NHANES). Multivariable-adjusted Cox proportional hazard models using propensity-score, were used to examine dose-response associations between Hcy level and mortality. A total of 9895 participants, 1025 (10.3%) participants were diagnosed with CKD. In a multivariate Cox regression analysis including all participants, Hcy level was significantly associated with all-cause mortality in the nonCKD group, compared to the 1st quartile in the fully adjusted model (2nd quartile: hazard ratio (HR) 1.75, 95% confidence interval (CI) 1.348–2.274, P < .001; 3rd quartile: HR 2.22, 95% CI 1.726–2.855, P < .001; 4th quartile: HR 3.77, 95% CI 2.952–4.830, P < .001). However, this finding was not observed in the CKD group. The observed pattern was similar after propensity score matching. In the nonCKD group, overall mortality increased in proportion to Hcy concentration (2nd quartile: HR 2.19, 95% CI 1.299–3.709, P = .003; 3rd quartile: HR 2.60, 95% CI 1.570–4.332, P < .001; 4th quartile: HR 3.72, 95% CI 2.254–6.139, P < .001). However, the risk of all-cause mortality according to the quartile of Hcy level, did not increase in the CKD group. This study found a correlation between the Hcy level and mortality rate only in the nonCKD group. These altered risk factor patterns may be attributed to protein-energy wasting or chronic inflammation status, that is accompanied by CKD.